Weight Loss Drugs Listed By Health Insurers Aren’t Necessarily Covered
Eli Lilly’s Foundayo weight loss oral pill competes against Novo Nordisk’s oral Wegovy. (Photo by: Michael Siluk/UCG/Universal Images…
An experimental GLP-1 pushes the limits of weight loss. There are risks.
Eli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity…
From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Eli Lilly saw…
Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
By Bhanvi Satija and Chris Prentice LONDON/NEW YORK, May 21 (Reuters) – Lower prices for weight-loss pills from…
Could Eli Lilly’s Next Weight Loss Drug Waylay Wegovy — and Even Zap Zepbound?
After losing its market edge to Eli Lilly (NYSE: LLY) despite its first-mover advantage in weight-loss drugs, Novo…
Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders
Novo Nordisk has shared new data that suggests a higher dose version of its blockbuster weight loss drug,…
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were…
‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s – National
Health Canada has approved a second drug that can slow the progression of Alzheimer’s disease. Donanemab, sold by…
Scoring 2 Million Prescriptions, Novo’s GLP-1 Pill Crushes Expectations
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built…
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.
Last year, Eli Lilly (NYSE: LLY) made history when it became the first healthcare company to reach a…
Novo Nordisk Expands GLP-1 Reach With Oral Ozempic And Pediatric Push
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Can Oral Ozempic and Label Expansions Revive NVO’s Near-Term Growth?
Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic…